子宫内膜癌前哨淋巴结定位:医疗废物改革的契机
该研究利用监测、流行病学和最终结果项目数据库及Premier数据库,估算子宫内膜癌前哨淋巴结定位中废弃吲哚菁绿(ICG)的年度成本。假设妇科肿瘤医生每例使用2-4 mL(20-40%)的现有ICG瓶装试剂盒(25 mg/10 mL),估计医院年度超额成本为2,729,825至3,639,767美元,患者和支付方年度废弃药物成本为13,308,999至17,745,332美元。作者建议将ICG瓶装为10 mg试剂盒(2-4 mL无菌溶液)以避免药物浪费。
要点
- 估计45,864例局限性子宫内膜癌病例符合前哨淋巴结定位条件。
- ICG平均总成本为99.20美元,平均收费为483.64美元。
- 作者建议ICG以10 mg瓶装试剂盒(2-4 mL无菌溶液)包装以减少浪费。
核心结论
- 作者建议ICG应包装为10 mg瓶装试剂盒(2-4 mL无菌溶液)以避免药物浪费及对机构和患者的财务影响。
研究设计与样本
- 利用监测、流行病学和最终结果项目数据库和Premier数据库,确定年度前哨淋巴结定位使用ICG的病例数及ICG对机构和患者的中位成本。
- 假设妇科肿瘤医生每例使用2-4 mL(20-40%)的现有ICG瓶装试剂盒(25 mg/10 mL)。
- 以成本作为机构浪费的衡量,以收费作为转移给患者或支付方的超额成本。
主要发现
- 估计45,864例局限性子宫内膜癌病例被识别并符合前哨淋巴结定位条件。
- ICG相关的平均总成本为99.20美元,平均收费为483.64美元。
- 医院年度超额成本估计为2,729,825至3,639,767美元。
- 使用平均收费数据,患者和支付方年度废弃药物成本为13,308,999至17,745,332美元。
临床怎么用
- 作者建议ICG瓶装为10 mg试剂盒(2-4 mL无菌溶液)以避免药物浪费和财务影响。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: As healthcare expenditures continue to rise, identifying mechanisms to reduce unnecessary costs is critical. The objective of this study is to estimate the annual cost of wasted indocyanine green (ICG) used for sentinel lymph node mapping in patients with endometrial cancer. METHODS: Using the Surveillance, Epidemiology, and End Results program database and Premier database, we determined the annual number of cases in which sentinel lymph node mapping with ICG would be used and the median cost of ICG to institutions and patients, respectively. We assumed that gynecologic oncologists use 2-4 mL (20-40%) of the currently available ICG vial kit (25 mg per 10 mL) per case. Estimated waste was then calculated using cost as a measure of institutional waste and charge as excess cost transferred to patients or payers. RESULTS: An estimated 45,864 cases of localized endometrial cancer were identified and eligible for sentinel lymph node (SLN) mapping. The mean total cost associated with ICG was 99.20 and the mean charge was $483.64. The estimated excess annual cost to hospitals was $2,729,825 to $3,639,767. Similarly, using mean charge data, the annual cost of wasted drug for patients and payers was $13,308,999 to $17,745,332. CONCLUSIONS: The annual cost of wasted ICG due to its current manufactured vial size exceeds $2 million for hospitals and $13.3-$17.7 million for patients. We suggest ICG vials should be packaged in a 10 mg vial kit (2-4 mL sterile solution) to avoid drug waste and the financial impact to institutions and patients.
引用
- Marsh LA, Aviki EM, Wright JD, et al. Sentinel lymph node mapping for endometrial cancer: Opportunity for medical waste reform. Gynecol Oncol. 2022. PMID: 35597685. doi:10.1016/j.ygyno.2022.05.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。